Fig 1: Gpr176 basal activity inhibits Vip–Vipr2–cAMP signalling.(a) Experimental schemes based on Flp-In TREx293-Gpr176(tet-on)/Vipr2 cells. (b) Immunoblots of Gpr176 and Vipr2 with cell membrane fractions of Flp-In TREx293-Gpr176(tet-on)/Vipr2 cells. Cells were treated with either 1 μg ml−1 Dox or control vehicle for 24 h. Gi was used as a loading control. (c) Confocal images of representative dual-label immunofluorescent staining of Gpr176 and Vipr2 in Dox-treated or non-treated Flp-In TREx293-Gpr176(tet-on)/Vipr2 cells. (d) Antagonistic basal activity of Gpr176 on Vip- and forskolin (Fsk)-stimulated cAMP accumulation in Flp-In TREx293-Gpr176(tet-on)/Vipr2 cells. Cells of the same batch were cultured in parallel with or without Dox for 24 h then resuspended in 0.5 mM IBMX (non-selective phosphodiesterase inhibitor)-containing assay buffer for 1 h and stimulated with Vip or Fsk for 15 min. Individual treatments were run in each experiment in triplicate. cAMP levels were determined by enzyme immunoassays. Values are expressed as mean±s.e.m. per 1 × 105 cells. ***P<0.001 in comparison with the control stimulated group. (e) Unaltered, dose-dependent [125I]-Vip binding activities of Dox-treated Flp-In TREx293-GPR176(tet-on)/Vipr2 cells. Values are means±s.e.m. of four independent experiments. (f) Immunoblots of mutant cell lines expressing either Gpr176RDY or Gpr176V145R. Point mutations were introduced into the conserved DRYxxV motif residues on Gpr176 in Flp-In TREx293-Gpr176(tet-on)/Vipr2 cells. Western blotting was done as described in b. (g) Diminished basal activities of Gpr176 by DRYxxV motif mutation. Dox-treated or non-treated cells were stimulated with Vip (100 nM), Fsk (10 μM), or vehicle then subjected to cAMP assays. Where specified, cells were treated with PTX (100 ng ml−1) for 16 h before assay. Each experiment was done in triplicate. cAMP values (means±s.e.m.) are plotted relative to those of Fsk-stimulated uninduced cells. ***P<0.001, **P<0.01 in comparison with the control stimulated group.
Fig 2: Gpr176 couples to Gz.(a) In situ hybridization of the gene encoding Gz (Gnaz) in the mouse SCN using a digoxigenin-labelled gene-specific probe. Scale bar, 100 μm. (b) Expressions of the genes encoding Gz (Gnaz), Gi1 (Gnai1), Gi2 (Gnai2) and Gi3 (Gnai3) in TREx293 (red) and NIH3T3 (blue) cells. Values (means±s.e.m.) were determined by qRT–PCR and normalized to those of the ribosomal phosphoprotein P0 (Rplp0)-encoding gene (n=3). (c) Interference of Gpr176-mediated cAMP repression by knocking down Gz protein with two different siRNA mixtures. For simplicity, Flp-In TREx293 cells bearing only Gpr176 were used (no concomitant Vipr2 expression in this assay). Cells were transfected with siRNAs for 96 h, with or without Dox for the final 24 h, and stimulated by Fsk (100 μM). Transfection was also performed with a negative-control siRNA (NC). Immunoblots show efficient knockdown of Gz. There was no off-target effect on Gi. NT, non-transfected cells. cAMP levels are plotted relative to those of Fsk-stimulated uninduced cells. Data are the mean±s.e.m. of at least two independent experiments with three replicates each. ***P<0.001 in comparison with the control stimulated group. NS, not significant. (d) Inactivation of Gpr176-mediated cAMP reduction by RGSZ1 coexpression. Cells were infected with lentiviruses encoding GFP (mock) or HA-tagged RGSZ1 and treated with or without Dox for 24 h. Western blot shows delivered proteins (anti-HA). cAMP values in Fsk-stimulated (100 μM) and nonstimulated (vehicle) cells are shown as described in c. (e) Interruption of Gpr176-mediated cAMP reduction by coexpression of DN-Gz. DN-Gz was stably introduced into the cells, and Dox-treated or non-treated cells were stimulated with Fsk (100 μM) or vehicle. Western blot (anti-Gz) shows the predominance of DN-Gz over the endogenous protein. cAMP values are expressed as described in c. (f) Generation and western blot confirmation of NIH3T3-based Tet-inducible Gpr176 cell lines with or without stable expression of Gz. Cells were treated with or without Dox and immunoblotted for indicated proteins. Note that Gz is scant in parental NIH3T3 cells. (g) cAMP repressive activities expressed by Gpr176 in NIH3T3 Gz(+) cells. Dox-treated or non-treated cells were stimulated with Fsk or vehicle. Where specified, cells were treated with PTX for 16 h before assay. cAMP values are expressed as described in c. (h) cAMP levels in the SCN of Gpr176+/+ and Gpr176−/− mice at CT4 and CT16 in DD. SCN punches taken from mice were subjected to cAMP quantification by using a cAMP-specific enzyme immunoassay kit. Each data point represents a single animal. Bars indicate means±s.e.m. for Gpr176+/+ CT4 (n=11), Gpr176−/− CT4 (n=12), Gpr176+/+ CT16 (n=11), and Gpr176−/− CT16 (n=11). ***P<0.001, two-way ANOVA with Bonferroni post hoc test.
Fig 3: mTOR is knocked down in VIP neurons in the SCN of Mtorflx/flx:Vip-Cre mice. (A) Confocal microscopic images of immunofluorescent labeling for p-S6 (red) and VIP (green) in the suprachiasmatic nucleus. For these experiments, the mice were entrained to a 12-h/12-h light/dark cycle and killed at ZT6. p-S6 and VIP expression was colocalized in the ventral SCN in Mtorflx/flx mice. Note that the number of cells coexpressing p-S6 and VIP (yellow) was decreased in the SCN of the Mtorflx/flx:Vip-Cre mice. Also note that intensities of p-S6 and VIP were both decreased in the ventral SCN. Framed regions are magnified and shown below. (Scale bars, 100 μm.) (B) Percentages of cells expressing p-S6, VIP, or both in the SCN. (C) Representative Western blots of forebrain lysates. (D) Quantitation of the blot intensities is shown. Values are presented as the mean ± SEM. Note that the level of prepro-VIP was markedly reduced in the Mtorflx/flx:Vip-Cre brain but VPAC2 level was not changed. mTOR and p-S6 levels were also significantly reduced. Four Mtorflx/flx and four Mtorflx/flx:Vip-Cre mice were used in the experiment. *P < 0.05 vs. Mtorflx/flx.
Fig 4: Characterization of histological and genetic relationships between Gpr176 and Vipr2.(a) Double-label immunofluorescence of Gpr176 and Vipr2 in the mouse SCN. Coronal brain sections were immunolabeled with antibodies against Gpr176 (rabbit polyclonal) and Vipr2 (chicken polyclonal). Representative confocal pictures are shown, with a merged image of Gpr176 (red) and Vipr2 (green). Scale bar, 100 μm. (b) Enlargement of the boxed area in (a). Merge shows combined images for Gpr176 (red), Vipr2 (green), and DAPI-based nuclear staining (blue). Scale bar, 20 μm. (c) Immunofluorescence and phase contrast (P.C.) images of dispersed SCN neurons. Cells were immunolabelled for Gpr176 and Vipr2. Merge shows combined images of Gpr176 (red), Vipr2 (green), and DAPI (blue). Scale bar, 20 μm. (d) Antiphasic circadian expression profiles of Gpr176 and Vipr2 in the SCN. Values (mean±s.e.m.) indicate relative immunoreactivities of Gpr176 and Vipr2 at 6 time points in DD (n=6 brains for each data point). Representative images of the immunolabeled SCN sections are shown on the top. Scale bar, 200 μm. (e–g) Representative double-plotted actograms and χ2 periodograms of locomotor activity rhythms of mice carrying wild-type, Gpr176−/− and Vipr2−/− alleles. Vipr2−/− mice exhibit a single (e) or multiple (f) circadian periods in DD, while all wild-type and Gpr176−/− mice had a single, stable circadian period (g). Diagonal line on periodogram shows significance at P<0.001. See also Supplementary Fig. 6. (h) Percentage of mice expressing a single dominant circadian period (black) or multiple circadian periods (grey). n=8−12 for each genotype. (i) Group data showing individual and combined effects of Gpr176−/− and Vipr2−/− on circadian period of locomotor activity rhythms. Values (mean±s.e.m.) indicate free-running periods of mice with a single dominant period in DD (n=5−8). ***P<0.001, one-way ANOVA with Bonferroni post hoc test.
Fig 5: Partial VPAC1 but not VPAC2 gene loss in BV2 microglia reduces nitric oxide (NO) release. The bar graph demonstrates a significant reduction in NO release in the culture media of VPAC1+/− but not in VPAC2+/− microglia. The results shown are the mean ± SEM of three independent experiments, each using four separate biological replicates per genotype (n = 12). ## p < 0.01 vs. WT and $ p < 0.05 vs. VPAC1+/− cells, as determined by one-way ANOVA, followed by Tukey post-hoc analysis. O.D. = optical density.
Supplier Page from Abcam for Anti-VPAC2 antibody